Abstract
Fimasartan is a novel angiotensin II receptor blocker with strong anti-hypertensive activity. In this study, a more rapid and sensitive ultra-performance liquid chromatography–tandem mass spectrometry (UPLC-MS/MS) method to determine fimasartan in human plasma was developed and fully validated. The quantification of analytes was conducted by MS/MS in a multiple reaction monitoring mode at m/z 502.2 → 207.1 for fimasartan and m/z 526.3 → 207.1 for the internal standard (IS, BR-A-563). The method showed a linear response from 3 to 1000 ng/mL (r > 0.9950). The intra- and inter-day accuracy values were 86.9 – 98.2 and 93.3 – 100.1%, respectively. The intra- and inter-day precision values were 2.0 – 3.1 and 0.8 – 8.0%, respectively. This UPLC-MS/MS method was validated for specificity, linearity, precision, accuracy, recovery, system suitability, and stability, and was found to be acceptable for bioanalytical applications. Finally, this fully validated method was successfully applied to a pharmacokinetic study of fimasartan in healthy volunteers following oral administration.
Similar content being viewed by others
References
P. M. Kearney, M. Whelton, K. Reynolds, P. Muntner, P. K. Whelton, and J. He, Lancet, 2005, 365, 217.
B. S. Heran, M. M. Wong, I. K. Heran, and J. M. Wright, Cochrane Database Syst. Rev., 2008, CD003822.
Y. H. Chi, J. H. Lee, J. H. Kim, H. K. Tan, S. L. Kim, J. Y. Lee, H. K. Rim, S. H. Paik, and K. T. Lee, Biol. Pharm. Bull., 2013, 36, 1208.
J. A. Cutler and B. R. Davis, Circulation, 2008, 117, 2691.
F. H. Messerli, D. G. Beevers, S. S. Franklin, and T. G. Pickering, Am. J. Hypertens., 2003, 16, 870.
M. E. Bertrand, Curr. Med. Res. Opin., 2004, 20, 1559.
E. Moutzouri, M. Florentin, M. S. Elisaf, D. P. Mikhailidis, and E. N. Liberopoulos, Curr. Vasc. Pharmacol., 2010, 8, 344.
S. E. Lee, Y. J. Kim, H. Y. Lee, H. M. Yang, C. G. Park, J. J. Kim, S. K. Kim, M. Y. Rhee, and B. H. Oh, Clin. Ther., 2012, 34, 552.
J. H. Kim, J. H. Lee, S. H. Paik, J. H. Kim, and Y. H. Chi, Arch. Pharm. Res., 2012, 35, 1123.
J. H. Lee, B. W. Yoo, J. H. Kim, H. K. Tan, and S. L. Kim, Drug Metab. Rev., 2006, 38, 154.
N. Gu, B. H. Kim, K. S. Lim, S. E. Kim, W. S. Nam, S. H. Yoon, J. Y. Cho, S. G. Shin, I. J. Jang, and K. S. Yu, Clin. Ther., 2012, 34, 1592.
B. S. Shin, T. H. Kim, S. H. Paik, Y. H. Chi, J. H. Lee, H. K. Tan, Y. Choi, M. Kim, and S. D. Yoo, Biomed. Chromatogr., 2011, 25, 1208.
S. H. Yoon, S. Oh, H. S. Kim, S. Yi, K. S. Yu, I. J. Jang, and J. Y. Cho, J. Chromatogr. Sci., 2015, 53, 1250.
K. J. Jang, B. W. Yoo, J. H. Lee, and S. L. Kim, Jpn. J. Pharmacol., 1999, 79, 195.
H. W. Lee, M. S. Lim, S. J. Seong, J. Lee, J. Park, J. J. Seo, J. Y. Cho, K. S. Yu, and Y. R. Yoon, Expert Opin. Drug Metab. Toxicol., 2011, 7, 1337.
K. H. Ni, Z. Wen, X. C. Huang, C. X. Wang, T. T. Ye, G. X. Hu, and M. T. Zhou, J. Chromatogr. B: Anal. Technol. Biomed. Life Sci., 2015, 990, 181.
B. Behnoush, A. Sheikhazadi, E. Bazmi, A. Fattahi, E. Sheikhazadi, and S. H. Saberi Anary, Medicine (Baltimore), 2015, 94, e640.
A. Kumar, G. Saini, A. Nair, and R. Sharma, Acta Pol. Pharm., 2012, 69, 371.
H. Jiang, U. H. Engelhardt, C. Thrane, B. Maiwald, and J. Stark, Food Chem., 2015, 183, 30.
U.S. Food Drug Administration; Guidance for industry, C. f. method validation. U.S. Food and Drug Administration and R. Drug Evaluation and Research, http://www.fda.gov/cder/guidance, 2001.
C. M. Nijenhuis, L. Lucas, H. Rosing, J. H. Schellens, and J. H. Beijnen, J. Chromatogr. B: Anal. Technol. Biomed. Life Sci., 2013, 940, 121.
H. J. Jung, M. R. Gwon, J. Park, J. J. Seo, S. J. Seong, E. H. Kim, S. R. Suh, J. Y. Jeong, H. W. Lee, and Y. R. Yoon, Anal. Sci., 2014, 30, 293.
X. Wang, Z. Zheng, G. He, L. Mai, Z. Zhou, S. Zhong, Q. Lin, Z. Shan, C. Deng, M. Yang, and X. Yu, J. Chromatogr. B: Anal. Technol. Biomed. Life Sci., 2015, 978 – 979, 78.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hyun, J.Y., Kim, HJ., Gwon, MR. et al. Fully Validated Ultra-performance Liquid Chromatography-Tandem Mass Spectrometry Method for the Determination of Fimasartan in Human Plasma. ANAL. SCI. 31, 1335–1339 (2015). https://doi.org/10.2116/analsci.31.1335
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.2116/analsci.31.1335